Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.42 USD | +0.57% | +1.30% | +84.56% |
01:59pm | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
05-13 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+84.56% | 294M | |
+29.67% | 48.16B | |
-1.19% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.15% | 25.59B | |
-22.97% | 18.96B | |
+7.92% | 12.92B | |
+29.14% | 12.03B | |
-1.95% | 11.77B |
- Stock Market
- Equities
- INO Stock
- News Inovio Pharmaceuticals, Inc.
- Inovio Pharmaceuticals : Roth Capital Downgrades Inovio Pharmaceuticals Back to Sell From Neutral; Price Target Remains $8